Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents

Similar documents
- 1 -

50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH

Acecide_ProductsInformation2010PDF.indd

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

感染症学雑誌第80巻第6号




名称未設定-1

DIC vegetation 1 nonbacterial thrombogenic e

untitled

HPM_442_F_TgCHG_1128

小動物の皮膚真菌症

日本皮膚科学会雑誌第122巻第2号


日本化学療法学会雑誌第50巻新薬特集号

第65回日本化学療法学会東日本支部総会 抄録

untitled

untitled


日本化学療法学会雑誌第56巻第3号


第82 回日本感染症学会総会学術集会後抄録(I)

IF MR 63 2 IF 10 3 IF IF IF A4 9 IF IF IF 11 1 IF IF IF MR IF IF MR Drug Safety Update IF

obayasshi1118.indd

1 Q A 82% 89% 88% 82% 88% 82%

第十五改正日本薬局方第一追補


日本化学療法学会雑誌第58巻第2号

日本皮膚科学会雑誌第119巻第5号


08サーベイ部会報告書v1117


Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS

DocuPrint C5450 ユーザーズガイド

et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology

Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST


Fig. 1 Chemical structure of DL-8280

_02.indd

2007 Vol.56 No.6 総説 丸山浩樹


37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

SBP hospitalist network.key

山口英世先生


988 CHEMOTHERAPY NOV. 1971



ヒビスコール液A カタログ

C/NC : committed/noncommitted


報告書 H22-2A-09


No.5

untitled

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

051

untitled

indd

Transcription:

D 012

Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents

DATA : 1 DATA : 2 3 DATA : UNGITEC 1

1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126) 2 1000 100 20 10 1 (13)--D(pg/mL)

FUNGITEC 3

DATA : 2 1. Candida albicans 2. Candida glabrata 3. Candida parapsilosis 4. Candida tropicalis 5. Candida guilliermondii 6. Aspergillus fumigatus 7. Aspergillus flavus 8. Aspergillus niger 9. Cryptococcus neoformans 10. Mucor sp. 11. Trichosporon beigelii 100 100 90 80 73.8 70 64.3 60 50 45.7 40 30 30.2 20 10 0 10.0 5.2 3.7 1.7 01145111219202930394054556465 4

FUNGITEC 5

DATA : 3 525.6 pg/ml Cryptococcus neoformans C. neoformans 19871112 (C) 39 38 37 1 5 10 15 20 25 30 5 10 15 20 25 30 100 50 0 525.6 459.2 (mg dl 1 ) 3.8 7.9 4.4 10.4 10.1 10.7 2.2 0.2 0.9 0.7 Pseudomonas aeruginosa 76.5 pg/ml 1987345 10 15 20 25 30 1 5 10 15 20 25 30 1 5 (C) 39 38 37 (pg ml 1 ) 100 80 60 40 20 0 76.5 (mg dl 1 ) (mm h 1 ) 0.0 0.9 12.1 8.2 5.1 3.1 0.4 0.3 0.2 0.1 0.2 0.0 6 99 107 102 94 50 32 31 17 10 6

FUNGITEC L2, Ph1, HL-4Extremely high risk group minor-bcr HL-4 VP-16Ara-C 34.2 pg /ml20 pg /ml 56 1 5 10 15 20 25 30 1 5 10 15 20 25 30 B 3g/ 200mg 300mg 140mg/kg 100mg 140mg/kg 100mg/kg 140mg/kg 6mg/kg 2T 30mg/kg 200mg/kg 25mg/kg 30mg () 40 39 38 37 36 60 52.2 30 34.2 25.8 18.6 0 100 100 100 100 200 500 1400 1800 3500 14,300 18,400 1500 1800 1500 (mg dl 1 ) 2.0 15.8 22.6 16.2 23.4 19.4 18.2 20.0 18.6 17.2 2.5 0.3 0.0 0.1 0 0 0 0 2 6.0 7.0 20.0 45.0 75.0 85.0 16.0 19.0 14.0 200mg 400mg 200mg 56 14 20 25 31 5 10 17 12 20 31 10 20 30 200mg/ B 15 20 25 30 4g/ 2g/ 400mg/ 2g/ 400mg/ 400mg/ 6g/ 400mg/ 4g/ 200mg/ 2g/ 400mg/ 4g/ 400mg / 400mg/ 400mg/ 160mg/ 20mg/ 400mg/ 2mg/ G-CSF 300g/300g/150g /75g / 2mg/ 300mg/ 10mg/ G-CSF 300g / 180mg/ 4g/ 0.3g/ () 40 39 38 37 36 (mg dl 1 ) 9.1 9.6 18.0 18.1 14.9 11.4 9.2 6.0 5.0 10.7 10.5 16.5 14.1 4 5.6 11.5 7.9 3.0 0.4 35.5pg/mL 91.9pg/mL 42.35pg/mL 30.43pg/mL 7

FUNGITEC (pg ml 1 ) 300 G test/es 200 100 0 CT 6/1 6 30 7/14 15 16 21 26 8/2 3 9 17 20 26 9/16 24 29 C. tropicalis C. tropicalis C. tropicalis C. tropicalis G test Es Candida tropicalis C. tropicalis C. tropicaliscandida Candida Candida albicans Aspergillus flavus Aspergillus fumigatus Cryptococcus neoformans Microsporum canis Trichophyton mentagrophytes Trichophyton rubrum Saccharomyces cerevisiae Staphylococcus epidermidis Staphylococcus aureus -Streptococcus hemolyticus 8

R R 9

10 R R R R R

D01228 28 1921 2325 0227001 D01228 250 R D01219 160 D01221 180 D01223 200 D01225 220 11

R 1. Reiss, E. : Molecular immunology of mycotic and actinomycotic infections, pp.11-14, Elsevier, New York (1986) 2., pp. 79-91, (1987) 3. Saito, H. et al. : Agr. Biol. Chem., 32, 1261-1269 (1968) 4. Obayashi, T. et al. : Clin. Chim. Acta, 147, 55-65 (1985) 5. Obayashi, T. et al. : Infect Immun., 53, 294-297 (1986) 6. Obayashi, T. et al. : Prog. Clin. Biol. Res., 231, 357-369 (1987) 7. 35,852-853 (1991) 8. Obayashi, T. et al. : J. Med.Vet.Mycol., 30, 275-280 (1992) 9. Miyazaki, T. et al. : J. Clin. Lab. Anal., 6, 315-318 (1992) 10. 67,384-385 (1993) 11. 94,329-333 (1993) 12. Rylander, R. and Goto, H. (eds) (1994) : Third glucan inhalation toxicity workshop. Commitee on organic dusts ICOH, report 1/94 13. 17,933-942 (1994) 14. Obayashi, T. et al. : Lancet., 345, 17-20 (1995) 15. pp.127-133 (1994) 16. pp.17-25 (1995) 17. pp.27-31 (1995) 18. pp.92-93 (1995) 19. Yasuoka, A. et al. : Clin. Diagn. Lab. Immunol., 3, 197-199 (1996) 20. Yoshida, M. : J. Lab. Clin. Med., 128, 103-114 (1996) 21., pp. 7-12 (1981) 22. Morita, T. et al. : FEBS Lett., 129, 318-321 (1981) 23. Prog. Med.,7,1075-1083 (1987) 24. Tanaka, S. et al. : Carbohydr. Res., 218, 167-174 (1991) 25. Aketagawa, J. et al. : J. Biochem., 113, 683-686 (1993) 26., 23, 413-419, (1995) 27., 166, 811-812, (1993) 28. Tamura, H. et al. : Clin. Chim. Acta, 226, 109-112 (1994) 29., pp. 12-18, (1996) 30. 44,528-532 (1996) R1.Iwasaki, H. et al. : A new diagnostic aid for deep mycosis associated with hematologic disease using (13) --D-glucan assay (G-test). Am. Soc. Mycrobiol., pp. 705-706 (1993) R2. (13) --D-glucan Miconazole CHEMOTHERPY,39, 59-65 (1991) R3. R4., 154, 283-287, (1990) R5. Opportunistic Fungus Infection, 74, 61-69, (1985) R6. fluconazolechemotherpy, 41, 1027-1032, (1993) R7. Iwama, A. et al. : Improved survival from fungaemia in patients with haematological malignancies : Analysis of risk factors for death and usefulness of early antifungal therapy. Eur. J. Haematol., 51, 156-160 (1993) R8. Hughes, W. T. et al. : Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. J. Infect. Dis., 161, 381-396 (1990) R9. Debra, K. et al. : Guidelaines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. J. Infect. Dis., 163, 201 (1991) R10. Hughes, W. T. et al. : Guidelaines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever. J. Infect. Dis., 163, 202-203 (1991) R11. Medicament News,1392, 1-3 (1993. 1. 25) R12. Medicament News,1392,4-6 (1993. 1. 25) R13. (13) --D-glucan endotoxin 1pp. 104-105 (1999) R14. Usami, M. et al. : Positive (13) --D-glucan in blood components and release of (13) --D-glucan from depth-type membrane filters for blood processing. TRANSFUSION : 42, 1189-1195 (2002) R15. (13) --D- pp. 43-44 (2005) R16. (13) --D- 100-00056-1 Tel. 03-5220-8953 Fax. 03-5220-8956 12 100-00056-1

100-0005 6-1 Telephone:03-5220-8953 Facsimile :03-5220-8956 E-mail : lal@seikagaku.co.jp URL : http://www.seikagaku.co.jp 2005. 6. 2T(U)